TCR2 Therapeutics reports positive interim results for gavo-cel in early-stage solid tumors trial
TCR2 Therapeutics has reported positive interim results from its phase 1 part of the phase 1/2 clinical trial of its T-cell therapy candidate gavo-cel in mesothelin-expressing solid tumors. The US-based clinical-stage cell therapy company said that as of the 30 June 2021 data cutoff, 17 patients, which include 12 mesothelioma, four ovarian cancer and one […]